PRT062607 (acetate)

PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models[1].[2].

Product Specifications

CAS Number

[1370261-98-5]

Product Name Alternative

P505-15 (acetate) ; PRT-2607 (acetate) ; BIIB-057 (acetate)

UNSPSC

12352005

Target

Apoptosis; FAK; Mixed Lineage Kinase; PAK; Pyk2; Src; Syk

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/prt062607-acetate.html

Purity

99.83

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(N4N=CC=N4)=C3)=O.OC(C)=O

Molecular Formula

C21H27N9O3

Molecular Weight

453.50

References & Citations

[1]Spurgeon SE, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. J Pharmacol Exp Ther. 2013 Feb;344 (2) :378-87.|[2]Coffey G, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther. 2012 Feb;340 (2) :350-9.